0001209191-20-028898.txt : 20200513 0001209191-20-028898.hdr.sgml : 20200513 20200513172034 ACCESSION NUMBER: 0001209191-20-028898 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200511 FILED AS OF DATE: 20200513 DATE AS OF CHANGE: 20200513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LERNER RICHARD A CENTRAL INDEX KEY: 0001316274 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 20874246 MAIL ADDRESS: STREET 1: THE SCRIPPS RESEARCH INSTITUTE STREET 2: 10550 N. TORREY PINES ROAD CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-11 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001316274 LERNER RICHARD A C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 1 0 0 0 Common Stock 11430 D Common Stock 2020-05-11 4 M 0 25000 2.74 A 97313 I Held by the Lerner Family Trust UAD 11/14/94 Common Stock 2020-05-11 4 S 0 3500 20.50 D 93813 I Held by the Lerner Family Trust UAD 11/14/94 Stock Option (right to buy) 2.74 2020-05-11 4 M 0 12500 0.00 D 2020-06-10 Common Stock 12500 0 D Stock Option (right to buy) 2.74 2020-05-11 4 M 0 12500 0.00 D 2020-12-21 Common Stock 12500 0 D Dr. Lerner may be deemed to beneficially own securities held by the Lerner Family Trust UAD 11/14/94 (the "Lerner Family Trust"). Dr. Lerner disclaims beneficial ownership of securities held by the Lerner Family Trust except to the extent of his pecuniary interest therein. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the exercise of options. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.51 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. All shares underlying this option have vested. /s/ Lawrence J. Hineline, Attorney-in-fact 2020-05-13